Differential expression of S100A2 and S100A4 in lung adenocarcinomas: Clinicopathological significance, relationship to p53 and identification of their target genes
Open Access
- 9 December 2005
- journal article
- Published by Wiley in Cancer Science
- Vol. 96 (12) , 844-857
Abstract
Previous studies suggest that some S100 proteins are involved in the progression of certain types of cancer. However, no comprehensive data is currently available on the expression of S100 family genes in lung adenocarcinomas. Oligonucleotide array, quantitative reverse transcription–polymerase chain reaction and western blot analyses of lung adenocarcinoma cell lines and bronchiolar epithelial cells (SAEC and NHBE) revealed that S100A2 and S100A4 were the most strikingly downregulated and upregulated members of the S100 family, respectively. Immunohistochemical analyses of 94 primary lung adenocarcinomas showed that positive S100A2 expression (33/94, 35.1%) was significantly associated with lymphatic invasion (P = 0.0233) and positive S100A4 expression (19/94, 20.2%) with vascular invasion (P = 0.0454). Interestingly, a strong inverse relationship was found between S100A4 and p53 expression (P = 0.0008). Survival analyses showed that S100A4 positivity was associated with poor patient prognosis (P = 0.042). S100A2 positivity was not associated with patient survival when the whole patient group was analyzed; however, S100A2 positivity was a favorable prognostic indicator in patients with p53‐negative tumors (P = 0.0448). Finally, we used oligonucleotide array analyses and identified potential S100A2 and S100A4 target genes involved in cancer progression: S100A2 induced RUNX3 and REPRIMO; S100A4 induced EZRIN, RUNX1 and WISP1; S100A2 repressed EGFR, NFKB2 and RELA2; and S100A4 repressed ANXA10 and IL1RN. Thus, the present study demonstrates involvement of S100A2 and S100A4 in the progression of lung adenocarcinomas and an inverse association between S100A4 and p53 expression, and provides a list of targets regulated by S100A2 and S100A4. (Cancer Sci 2005; 96: 844–857)Keywords
This publication has 42 references indexed in Scilit:
- S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature)Biochemical and Biophysical Research Communications, 2004
- S100P Stimulates Cell Proliferation and Survival via Receptor for Activated Glycation End Products (RAGE)Journal of Biological Chemistry, 2004
- Pharmacogenetics of Anticancer Drug Sensitivity in Non-Small Cell Lung CancerPharmacological Reviews, 2003
- RUNX transcription factors as key targets of TGF-β superfamily signalingCurrent Opinion in Genetics & Development, 2003
- Gene-expression profiles predict survival of patients with lung adenocarcinomaNature Medicine, 2002
- Down-Regulation of Annexin A10 in Hepatocellular Carcinoma Is Associated with Vascular Invasion, Early Recurrence, and Poor Prognosis in Synergy with p53 MutationThe American Journal of Pathology, 2002
- Expression profiling of gastric adenocarcinoma using cDNA arrayInternational Journal of Cancer, 2001
- Association of COOH-terminal-binding Protein (CtBP) and MEF2-interacting Transcription Repressor (MITR) Contributes to Transcriptional Repression of the MEF2 Transcription FactorJournal of Biological Chemistry, 2001
- Aberrant rel/nfkb genes and activity in human cancerOncogene, 1999
- Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cellsOncogene, 1997